PAVM - PAVmed Inc Stock Price, Fair Value and News

1.80USD-0.08 (-4.26%)Delayed as of 17 May 2024, 12:48 pm ET

Market Summary

USD1.80-0.08

Delayedas of 17 May 2024, 12:48 pm

-4.26%

PAVM Stock Price

View Fullscreen

PAVM RSI Chart

PAVM Valuation

Market Cap

17.7M

Price/Earnings (Trailing)

-0.29

Price/Sales (Trailing)

5.88

EV/EBITDA

0.11

Price/Free Cashflow

-0.36

PAVM Price/Sales (Trailing)

PAVM Profitability

Operating Margin

-126.08%

EBT Margin

-2505.35%

Return on Equity

298.69%

Return on Assets

-164.96%

Free Cashflow Yield

-277%

PAVM Fundamentals

PAVM Revenue

Revenue (TTM)

3.0M

Rev. Growth (Yr)

126.46%

Rev. Growth (Qtr)

-3.72%

PAVM Earnings

Earnings (TTM)

-61.5M

Earnings Growth (Yr)

15.16%

Earnings Growth (Qtr)

-8.38%

Breaking Down PAVM Revenue

52 Week Range

0.211.95

(Low)(High)

Last 7 days

-16.4%

Last 30 days

0.5%

Last 90 days

-14.5%

Trailing 12 Months

308.7%

How does PAVM drawdown profile look like?

PAVM Financial Health

Current Ratio

0.54

PAVM Investor Care

Shares Dilution (1Y)

35.34%

Diluted EPS (TTM)

-9.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.0M	0	0	0
2023	634.0K	800.0K	1.5M	2.5M
2022	469.3K	438.5K	407.8K	377.0K
2021	0	0	0	500.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of PAVmed Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 22, 2024	baxter timothy e	acquired	-	-	65,000	-
Feb 22, 2024	sparks ronald m	acquired	-	-	65,000	-
Feb 22, 2024	glennon michael j	acquired	-	-	65,000	-
Feb 22, 2024	cox james l	acquired	-	-	65,000	-
Feb 22, 2024	white debra	acquired	-	-	65,000	-
Feb 22, 2024	harvey joan b	acquired	-	-	65,000	-
Dec 07, 2022	glennon michael j	bought	62,320	0.6232	100,000	-
Dec 06, 2022	glennon michael j	bought	56,082	0.6373	88,000	-
Dec 05, 2022	glennon michael j	bought	42,606	0.6872	62,000	-
May 04, 2022	o'neil shaun	sold (taxes)	-35,790	1.38	-25,935	chief operating officer

Which funds bought or sold PAVM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-41,543	44,899	-%
May 15, 2024	MORGAN STANLEY	added	98.49	330	10,976	-%
May 15, 2024	FIRST MANHATTAN CO. LLC.	added	112	85,500	909,500	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-7.00	4.00	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-53.33	-46.00	15.00	-%
May 15, 2024	Rockbridge Investment Management, LCC	sold off	-100	-112	-	-%
May 15, 2024	XML Financial, LLC	reduced	-2.58	-21,033	21,543	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	-2.00	2.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-34.86	-10,283	5,258	-%
May 15, 2024	Royal Bank of Canada	reduced	-71.05	-	-	-%

Are Funds Buying or Selling PAVM?

Are funds buying PAVM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PAVM

No. of Funds

Unveiling PAVmed Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ayrton capital llc	9.9%	851,018	SC 13G
Jul 08, 2022	blackrock inc.	1.6%	1,440,200	SC 13G
Feb 04, 2022	blackrock inc.	5.4%	4,786,168	SC 13G
Oct 06, 2021	sirovich matthew	2.9%	2,504,244	SC 13G/A
Jan 26, 2021	sirovich matthew	8.4%	5,539,750	SC 13G/A
Feb 14, 2020	sirovich matthew	14.4%	5,926,910	SC 13G/A

Recent SEC filings of PAVmed Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 13, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
May 01, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 26, 2024	8-K	Current Report
Mar 25, 2024	10-K	Annual Report
Mar 14, 2024	8-K	Current Report

Peers (Alternatives to PAVmed Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.4B	40.3B	-3.99%	-3.65%	32.43	4.52	-2.84%	-3.08%
BDX	68.4B	19.7B	2.45%	-5.81%	51.31	3.47	4.82%	-17.56%
ALGN	20.6B	3.9B	-10.40%	-6.17%	44.52	5.25	5.72%	46.72%
BAX	17.9B	14.9B	-11.17%	-17.84%	6.76	1.2	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.44%	23.99%	31.25	2.76	6.16%	35.06%
HSIC	9.5B	12.5B	4.37%	-2.87%	24.53	0.76	-0.61%	-18.83%
BIO	8.4B	2.6B	0.92%	-22.34%	-26.13	3.23	-6.25%	-68.62%
XRAY	5.9B	3.9B	-7.86%	-29.32%	-63	1.5	0.23%	91.03%
AXNX	3.5B	387.1M	0.46%	29.28%	-216.68	8.92	30.82%	65.57%
PDCO	2.3B	6.6B	0.82%	-4.37%	11.97	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	2.50%	-12.21%	-1.88	0.4	7.94%	-1661.78%
ANIK	378.1M	169.3M	-	-1.96%	-4.92	2.23	7.49%	-244.90%
ANGO	257.2M	324.0M	-1.38%	-32.77%	-1.34	0.79	-3.19%	-337.41%
APYX	53.0M	50.5M	10.79%	-74.07%	-2.32	1.05	14.25%	-10.06%
AEMD	1.0M	3.7M	-72.22%	29.03%	-0.09	0.28	5.77%	8.23%

PAVmed Inc News

Latest updates

PAVmed Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)											(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-3.7%	1,010,000	1,049,000	791,000	166,000	446,000	112,000	76,000	-	189,000	194,500	200,000
Cost Of Revenue	8.3%	1,744,000	1,610,500	1,779,000	1,685,000	1,346,000	1,618,500	1,626,000	-	369,000	-	144,000
Gross Profit	-	-	-	-	-	-	-	-	-	-180,000	-	56,000
Costs and Expenses	-13.7%	15,046,000	17,431,500	16,319,000	16,650,000	20,847,000	24,713,000	23,443,000	23,484,000	19,824,000	-	13,868,000
Operating Expenses	-	-	-	-	-	-	-	-	23,477,000	19,280,000	19,537,500	13,724,000
S&GA Expenses	-8.1%	4,311,000	4,689,500	4,016,000	4,339,000	4,539,000	5,759,000	4,736,000	4,898,000	3,925,000	3,340,000	2,293,000
R&D Expenses	-42.9%	1,941,000	3,401,000	3,161,000	3,469,000	4,439,000	6,569,000	6,202,000	6,740,000	5,932,000	6,969,000	5,305,000
EBITDA Margin	22.3%	-23.99	-30.89	-54.64	-113	-160	-263	-233	-183	-138	-111	-
Interest Expenses	-15.8%	16,000	19,000	159,000	228,000	183,000	-	525,000	523,000	-	-	-
Earnings Before Taxes	-6.3%	-18,512,000	-17,407,500	-21,750,000	-17,892,000	-22,214,000	-24,572,000	-29,932,000	-29,101,000	-19,633,000	-19,678,500	-13,668,000
EBT Margin	22.5%	-25.05	-32.33	-57.05	-118	-166	-273	-241	-187	-139	-112	-
Net Income	-8.4%	-15,212,000	-14,036,000	-17,671,000	-14,537,000	-17,931,000	-20,460,000	-26,126,000	-25,525,000	-16,872,000	-17,218,000	-12,227,000
Net Income Margin	22.1%	-20.38	-26.17	-46.60	-98.82	-142	-236	-210	-163	-123	-100	-
Free Cashflow	-9.1%	-13,151,000	-12,057,000	-11,107,000	-12,801,000	-16,313,000	-17,121,000	-19,657,000	-22,910,000	-12,837,000	-18,054,000	-8,053,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	12.5%	37.00	33.00	42.00	54.00	65.00	54.00	72.00	82.00	84.00	87.00	43.00	47.00	51.00	20.00	11.00	9.00	10.00	7.00	4.00	7.00	4.00
Current Assets	20.7%	30.00	24.00	32.00	43.00	54.00	44.00	62.00	71.00	71.00	83.00	42.00	46.00	51.00	19.00	10.00	8.00	9.00	7.00	4.00	7.00	4.00
Cash Equivalents	30.0%	26.00	20.00	26.00	37.00	49.00	40.00	57.00	65.00	65.00	77.00	37.00	43.00	49.00	17.00	8.00	7.00	9.00	6.00	4.00	7.00	4.00
Inventory	47.5%	0.00	0.00	-	-	-	0.00	-	-	-	-	0.00	-	-	-	-	-	-	-	-	-	-
Net PPE	-10.5%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	0.00	-	-	0.00	-	-	-	-	0.00	0.00	0.00
Liabilities	1.2%	58.00	57.00	58.00	55.00	54.00	43.00	44.00	41.00	20.00	8.00	8.00	5.00	3.00	20.00	25.00	22.00	26.00	12.00	7.00	9.00	10.00
Current Liabilities	1.5%	55.00	54.00	55.00	51.00	51.00	41.00	42.00	39.00	17.00	8.00	-	-	-	-	25.00	22.00	-	12.00	-	-	-
Shareholder's Equity	14.3%	-20.57	-24.02	-	-	11.00	11.00	29.00	41.00	65.00	79.00	35.00	42.00	48.00	2.00	-	-	-	-	-	-	-
Retained Earnings	-5.2%	-309	-294	-278	-260	-246	-228	-207	-181	-155	-138	-121	-109	-97.78	-88.27	-79.46	-73.91	-68.26	-53.71	-47.40	-44.25	-40.59
Additional Paid-In Capital	0.1%	238	238	232	226	221	216	214	201	200	198	154	150	145	88.00	64.00	60.00	51.00	48.00	43.00	41.00	33.00
Shares Outstanding	6.9%	9.00	9.00	8.00	7.00	7.00	6.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00	-	-	-	-	-	-	-	-
Minority Interest	61.7%	48.00	30.00	27.00	31.00	33.00	21.00	20.00	19.00	19.00	18.00	0.00	-0.91	-2.25	-2.37	-1.86	-1.48	-1.23	-0.81	-0.52	-0.34	-0.23
Float	-	-	-	-	39.00	-	-	-	71.00	-	-	-	470	-	-	-	82.00	-	-	-	30.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-10.4%	-13,109	-11,874	-11,089	-12,786	-16,287	-16,823	-19,341	-22,558	-12,263	-16,777	-8,018	-6,628	-9,168	-6,728	-5,840	-5,555	-3,791	-4,090	-2,878	-2,519	-3,870
Share Based Compensation	-4.4%	1,882	1,968	2,245	2,507	4,419	4,948	4,764	5,007	4,814	4,380	3,990	5,203	1,436	586	586	529	344	394	330	388	459
Cashflow From Investing	77.0%	-42.00	-183	-18.00	-15.00	974	-298	-1,316	-2,552	-574	-3,377	-135	-168	-36.00	-8.00	-3.00	-42.00	-2.00	-2.00	-	-22.00	-3.00
Cashflow From Financing	260.2%	19,048	5,288	352	684	24,849	80.00	12,289	25,526	316	60,071	2,284	1,460	40,494	15,699	7,056	3,946	6,305	6,214	67.00	5,259	-159

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PAVM Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Income Statement [Abstract]

Revenue

$ 1,010

$ 446

Operating expenses:

Cost of revenue

1,744

1,346

Sales and marketing

4,311

4,539

General and administrative

6,678

10,407

Amortization of acquired intangible assets

372

505

Research and development

1,941

4,050

Total operating expenses

15,046

20,847

Operating loss

(14,036)

(20,401)

Other income (expense):

Interest income

121

Interest expense

(16)

(183)

Change in fair value - Senior Secured Convertible Notes

(2,163)

(1,040)

Loss on issue and offering costs - Senior Secured Convertible Note

(1,186)

Debt extinguishments loss - Senior Secured Convertible Notes

(369)

(525)

Debt modification expense

(2,000)

Gain on sale of intellectual property

1,000

Other income (expense), net

(4,476)

(1,813)

Loss before provision for income tax

(18,512)

(22,214)

Provision for income taxes

Net loss before noncontrolling interests

(18,512)

(22,214)

Net loss attributable to the noncontrolling interests

3,300

4,283

Net loss attributable to PAVmed Inc.

(15,212)

(17,931)

Less: Series B Convertible Preferred Stock dividends earned

(80)

(74)

Less: Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests

(7,496)

Net loss attributable to PAVmed Inc. common stockholders

$ (22,788)

$ (18,005)

Per share information:

Net loss per share attributable to PAVmed Inc. common stockholders - basic

^[1]

$ (2.62)

$ (2.78)

Net loss per share attributable to PAVmed Inc. common stockholders - diluted

^[1]

$ (2.62)

$ (2.78)

Weighted average common shares outstanding, basic

8,694,904

6,473,010

Weighted average common shares outstanding, diluted

8,694,904

6,473,010

[1]

- Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.

PAVM Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 25,536	$ 19,639
Accounts receivable	67	61
Inventory	410	278
Prepaid expenses, deposits, and other current assets	3,561	4,520
Total current assets	29,574	24,498
Fixed assets, net	1,595	1,783
Operating lease right-of-use assets	3,886	4,267
Intangible assets, net	1,052	1,424
Other assets	1,147	1,147
Total assets	37,254	33,119
Current liabilities:
Accounts payable	1,485	1,786
Accrued expenses and other current liabilities	6,657	6,626
Operating lease liabilities, current portion	1,333	1,565
Senior Secured Convertible Notes - at fair value	45,540	44,200
Total current liabilities	55,015	54,177
Operating lease liabilities, less current portion	2,814	2,960
Total liabilities	57,829	57,137
Commitments and contingencies (Note 8)
Stockholders’ Equity:
Preferred stock, $0.001 par value. Authorized, 20,000,000 shares; Series B Convertible Preferred Stock, par value $0.001, issued and outstanding 1,331,336 at March 31, 2024 and 1,305,213 shares at December 31, 2023	3,071	2,993
Common stock, $0.001 par value. Authorized, 50,000,000 shares; 8,858,597 and 8,578,505 shares outstanding as of March 31, 2024 and December 31, 2023, respectively	9	9
Additional paid-in capital	237,863	237,600
Accumulated deficit	(309,723)	(294,433)
Total PAVmed Inc. Stockholders’ Equity (Deficit)	(68,780)	(53,831)
Noncontrolling interests	48,205	29,813
Total Stockholders’ Equity (Deficit)	(20,575)	(24,018)
Total Liabilities and Stockholders’ Equity (Deficit)	$ 37,254	$ 33,119

About PAVmed Inc

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

CEO	Dr. Lishan Aklog M.D.
WEBSITE	pavmed.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	124

PAVmed Inc Frequently Asked Questions

What is the ticker symbol for PAVmed Inc? What does PAVM stand for in stocks?

PAVM is the stock ticker symbol of PAVmed Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PAVmed Inc (PAVM)?

As of Thu May 16 2024, market cap of PAVmed Inc is 17.73 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PAVM stock?

You can check PAVM's fair value in chart for subscribers.

What is the fair value of PAVM stock?

You can check PAVM's fair value in chart for subscribers. The fair value of PAVmed Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of PAVmed Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PAVM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is PAVmed Inc a good stock to buy?

The fair value guage provides a quick view whether PAVM is over valued or under valued. Whether PAVmed Inc is cheap or expensive depends on the assumptions which impact PAVmed Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PAVM.

What is PAVmed Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, PAVM's PE ratio (Price to Earnings) is -0.29 and Price to Sales (PS) ratio is 5.88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PAVM PE ratio will change depending on the future growth rate expectations of investors.